Filgrastim-Mobilized Stem Cells for Transplantation Using Unrelated Donors
Recruiting now · Phase 3
Conditions studied: Healthy
In brief
The purpose of the study is to: * Establish and evaluate a system for collection of filgrastim-mobilized peripheral blood stem cells from National Marrow Donor Program donors (NMDP) donors * Assess the safety among NMDP donors of filgrastim administration and PBSC leukapheresis * Assess the safety and efficacy of filgrastim-mobilized PBSC in unrelated donor hematopoietic stem cell transplant recipients * Determine the acceptability of stem cell donation by filgrastim stimulated apheresis in normal donors
Key facts
- Study ID
- NCT00785525
- Run by
- Center for International Blood and Marrow Transplant Research
- People needed
- 60000
- Starts
- 1997-02-01
- Expected to finish
- 2030-01-01
- Last updated by the study team
- 2025-04-13
Who can join
Age: 18 and older, up to 60. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- PBSC donors must meet the same criteria as NMDP marrow donors. These criteria are set forth in the Donor Center Manual of Operations.
- Confirmatory pregnancy test must be performed within 15 days of collection and prior to the start of filgrastim administration; this may require more than one test to be performed.
You may not qualify if…
- Pregnancy or uninterruptible breastfeeding. Pregnancy is an absolute contraindication under this protocol. Women who are breastfeeding must be willing and able to interrupt breastfeeding during the administration of filgrastim and for two days following the final dose.
- Sensitivity to filgrastim or to E. coli-derived recombinant protein products.
- History of autoimmune disorders, including rheumatic diseases and thyroid disorders. Exception: As with bone marrow donations, donors with a history of thyroid disease who have undergone successful therapy may be suitable.
- History of deep vein thrombosis or pulmonary embolism.
- History of iritis or episcleritis.
- Thrombocytopenia < 150 x 10\^9/L (< 150,000/uL) at baseline evaluation.
- Current treatment with lithium. Drug interactions between filgrastim and lithium, which may potentiate the release of neutrophils, have not been fully evaluated.
- Positive Hemoglobin-Solubility (e.g., SickleDex or equivalent) test.
- Donors receiving experimental therapy or investigational agents.
- Positive pregnancy test collected/reported prior to start of filgrastim.
Where it is running
- Gift of Life Bone Marrow Foundation — Boca Raton, Florida, United States (enrolling)
- C.W. Bill Young Marrow Donor Center — Rockville, Maryland, United States (enrolling)
- Be The Match — Minneapolis, Minnesota, United States (enrolling)
- DKMS Americas — New York, New York, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.